Repligen Has $810 Million in Liquidity Amid $600 Million in Outstanding Notes
Key Facts
Repligen disclosed $600 million in aggregate principal amount of outstanding senior convertible notes, according to its quarterly filing with the U.S. Securities and Exchange Commission. The notes carry a 1.00% stated annual interest rate, while their effective interest rate is 4.39%. They mature on December 15, 2028, unless redeemed, repurchased or converted earlier. The obligation sets a deadline for repaying or otherwise addressing the debt before the end of 2028. Details of a new $1 billion issuance and its terms were not verified by an open source among the information available.
The company had $810 million in cash, cash equivalents and marketable securities as of June 30, 2026, according to its second-quarter results. The figure shows its liquid resources at that date, before the fiscal year was complete. The size of any bond issuance is not equal to the total cash a company receives, since an offering may involve the exchange of existing debt or other arrangements. By comparison, the outstanding notes have a principal amount of $600 million, while the liquidity figure combines cash and marketable securities. These figures are as of June 30 and do not represent an update on liquidity in October.
The outstanding notes are part of earlier financing announced by the company. When pricing them in December 2023, Repligen set an initial conversion price of $203.06 per share. That price represented a 30% conversion premium to the closing share price of $156.20 on December 6, 2023. The earlier terms show the price level associated with the option to convert the notes into shares at issuance. They do not establish the terms of any new offering or allow its conversion price to be inferred. The earlier notes remain due in December 2028, according to the quarterly filing.
The financing backdrop comes in a year in which Repligen agreed to acquire BioLife Solutions. According to the quarterly filing, the company entered into the agreement on July 21, 2026, for approximately $1.5 billion. The agreed consideration consists of about 64% common stock and 36% cash, with the deal expected to close in the fourth quarter of 2026. The filing said the cash portion of the consideration would be funded from available cash. This places liquidity and financing obligations in the context of the company's expansion, without by itself specifying how any additional financing would be used.
On the operating front, Repligen reported second-quarter 2026 revenue of about $204 million, up 12% year over year on a reported basis and 13% on an organic basis. The performance provides context for the company's business growth during the same period in which it reported liquidity of $810 million. The difference between the two growth rates also reflects how reported revenue is calculated compared with organic growth. These are second-quarter figures and are not presented here as results for a later period. The company's shares, RGEN, closed at $188.64 on October 29, according to EL7 data.
In its second-quarter filing, the company said the contingent conversion conditions were not met during the quarter ended June 30, 2026. As a result, the notes were not convertible during the quarter ended September 30 under the stock-price condition cited in the filing. This disclosure concerns the outstanding notes and does not determine their status after September 30. Their stated maturity remains December 15, 2028, unless they are redeemed, repurchased or converted earlier. The available information did not specify a later date concerning the notes.